demo_content_case_3A_link_3
RhythmGuard X1
continuous-monitoring platform
Surveillance, before the event.
A convertible wearable-to-implantable continuous-monitoring platform with five-channel sensing — including an integrated transcutaneous biochemical channel — and three-state autonomous operation. Designed for clinicians and health systems that intend to read the trajectory rather than only the strip.
integrated into one
trajectory index
sampling interval
(passive state)
states with auto-
escalation logic
wear cycle, with
swap-pad refresh
One platform, two form factors, one continuous patient signature.
RhythmGuard X1 is engineered as a single platform with two physical implementations — a wearable patch for outpatient evaluation and risk-trajectory profiling, and an implantable form for patients whose trajectory escalates to permanent monitoring. The firmware, the algorithms, and the per-patient signature trained during the wearable phase carry across the transition without re-training.
Convertible platform schematic. The wearable phase profiles the patient-specific signature; the implantable phase carries that signature across the form-factor transition without re-training. Stylized; not to scale.
Wearable form factor
Patch class, ~25 g, axillary biaxial placement, 14-day continuous-wear cycle with swap-pad refresh. Three skin-surface electrodes producing a six-lead reconstruction. All five sensing channels active. Designed for outpatient evaluation, pre-procedural risk-trajectory profiling, and post-discharge surveillance.
Implantable form factor
Subcutaneous, ~14 cc — sized between an insertable cardiac monitor and a small implantable defibrillator — pectoral pocket placement. Three intracardiac vectors. Therapeutic capability enabled (programmable ATP, cardioversion, defibrillation tiers). For patients whose risk-trajectory crosses the implantable threshold during the wearable evaluation phase.
CHEMOCARDIA-ENGINE algorithm
The proprietary inference engine that combines transcutaneous Raman and impedance spectroscopy with population calibration to produce continuous estimates of serum potassium, magnesium, calcium, blood pH, and circulating levels of monitored antiarrhythmic and anticoagulant drugs.
Disclosure expected Q4 2026Cohort-cohort signature transfer
The mechanism that lets the patient signature trained during the wearable evaluation phase carry across the form-factor transition without retraining. Calibrates trajectory features across surface and intracardiac vectors so that alert thresholds remain stable through the convertibility step.
Available under institutional MSAFive signal classes. One integrated trajectory.
The trajectory index that drives RhythmGuard X1’s autonomous escalation logic is computed from five separate sensing channels, sampled continuously and integrated by the platform’s inference engine. The biochemical channel — channel 02 — is the differentiating addition that conventional rhythm-only monitoring substrates do not provide.
Multi-vector ECG
Six-lead reconstruction from three surface electrodes (wearable) or three intracardiac vectors (implant). The rhythm-recognition channel.
Photonic biochemistry
Transcutaneous Raman + impedance spectroscopy. K⁺, Mg⁺, Ca⁺, blood pH, and serum levels of monitored antiarrhythmics and anticoagulants.
Hemodynamic pulse
Cuff-less peripheral perfusion pulse, blood-pressure trend, and pulse-transit time. Hemodynamic context for rhythm events.
Activity & autonomic
Heart-rate variability, accelerometer-derived activity and posture, sleep state classification. The autonomic-drift channel.
Trans-thoracic impedance
Bioimpedance estimating fluid status, pulmonary congestion trend, and respiratory rate. Loads as a slow congestion variable.
Surveillance escalates by itself, before the team is paged.
RhythmGuard X1 operates in three programmable states with auto-escalation logic. The platform raises its own sampling rate and pre-positions therapy circuits when the integrated trajectory index crosses a learned threshold — before any clinician has been paged and before any rhythm has yet been confirmed.
Baseline surveillance
Low-power continuous sampling on all five channels at baseline rates. Trajectory index updated at 30 s intervals. No clinician action required. Weekly summary delivered to the responsible clinician through the platform dashboard.
Pre-positioned readiness
Auto-engaged when the integrated trajectory index crosses a learned threshold. Sampling rate increases. Electrolyte and drug-level recheck every 60 s. Therapy circuits pre-positioned (implant) or alarm circuits pre-staged (wearable). Patient receives a haptic pre-alert.
Intervention-ready
Engaged once a sustained dysrhythmia is confirmed at the rhythm channel. Implantable form: programmed therapy tier delivered (anti-tachycardia pacing, synchronised cardioversion, defibrillation). Wearable form: alarm sounded, patient app activated, full notification cascade dispatched.
Five hops, configurable timeouts, fail-safe routing.
Cascade timing parameters are configurable per patient and per institutional policy; the values shown are platform defaults. The 911 / EMS dispatch payload includes patient location, the last 90 seconds of multi-channel data, and the most recent biochemical estimates.
RhythmGuard X1 versus the alternatives.
Comparative positioning across four continuous-monitoring substrates and the conventional outpatient Holter baseline. All comparator entries are illustrative composites for this demonstration; they do not represent any real licensed product or any specific real medical device.
| X1 PLATFORM RhythmGuard X1 convertible · this product | LinealCardio Patch wearable patch only | CycardX Implantable implant only | OmniRhythm CGM-style subdermal patch | Conventional Holter 24–72 h outpatient | |
|---|---|---|---|---|---|
| Form factor | Convertible wearable + implant | Wearable patch only | Implant only | Subdermal patch | External Holter monitor |
| Continuous wear duration | ~ 14 mo wearable + indefinite implant | ~ 14 days | indefinite | ~ 90 days | 24–72 hours |
| Multi-vector ECG | Yes · 6-lead reconstruction | Partial · 1-lead | Yes · 3 intracardiac vectors | Partial · 1-lead | Yes · 3-lead surface |
| Biochemical channel | Yes · transcutaneous spectroscopy | No | No | No | No |
| Hemodynamic channel | Yes · cuff-less pulse + impedance | No | Partial · trans-thoracic impedance only | No | No |
| Autonomous state escalation | Yes · passive / vigilant / therapeutic | No · constant sampling | Partial · sampling rate adapts | No | No |
| Therapeutic capability | Yes (implant) · ATP / cardioversion / defib | No | Yes · defib only | No | No |
| Notification cascade | Yes · 5-hop, fail-forward | Partial · clinician portal | Partial · clinician portal | Partial · clinician portal | No · post-recording review only |
Entries reflect the demonstration positioning of fictional comparator devices; specific feature parities should be verified against the public technical documentation of any real device under evaluation. RhythmGuard X1 itself is described in this demonstration as if at full feature parity; in any real product timeline, regulatory clearance and feature availability would govern actual deployment scope.
Two cohorts. One platform. The full convertibility cycle observed in service.
Cohort 2024-W enrolled patients on the wearable form for risk-trajectory profiling. Cohort 2024-I followed the subset who escalated to the implantable form during the wearable phase. The convertibility step — carrying the patient signature across the form-factor transition without retraining — is what these cohorts were designed to characterise. All cohort data shown is illustrative composite for this demonstration.
Wearable phase, mixed indications
enrolled
pre-event
at 6 months
Cohort enrolled Q1–Q2 2024 · 12-month wearable phase · figures are illustrative composites
Implantable transition subset
converted
recovery time
required
Subset converted Q3 2024 · 6-month implant phase observed · figures are illustrative composites
The device that converts surveillance into prevention.
In adult emergency departments around the world, the same conversation happens every week. A young patient survives a presentation that should not, in modern medicine, ever be a first contact with the system. The team handles the rhythm correctly. The substrate is identified. Ablation candidacy is established as a survivor referral. RhythmGuard X1 was developed because the case in front of those teams was not a rhythm-recognition failure — it was a surveillance failure that occurred weeks earlier, on a substrate that was visible to the right monitor and to nothing else.
The substrate was visible on his ECG fourteen months earlier. We had it on file. Nobody read it. Nobody could have, on the system we had then. The wearable would have caught the trajectory. The implant would have ended the conversation. This is the difference between consenting a twenty-six-year-old in clinic on a Tuesday morning and consenting a family in an ICU corridor at six in the morning. We owe that difference to the patient, to the team, and to the next patient on the same trajectory whose chart is sitting unread in an employment file right now.
— Composite illustrative cardiology faculty narrative · 2025
Built for the clinician at the bedside and for the system that funds the pathway.
RhythmGuard X1 was designed from the start to deliver value at two different scales: the individual clinician using a continuous substrate to read a specific patient’s trajectory, and the health system accountable for the population economics of arrhythmia care. The platform, the metrics, and the contractual structure are different at each level.
Surveillance with the channels you actually want.
The unit is the trajectory. The biochemical channel is included. The substrate-risk gating step has somewhere to send the patient. The therapeutic capability is engaged only on rhythm confirmation, never on trajectory alone.
- Five-channel substrate · ECG, biochemistry, hemodynamic, autonomic, impedance — integrated into a single trajectory index.
- Convertible form factor · wearable for outpatient evaluation, implant for patients whose trajectory escalates — same patient signature.
- Three-state autonomy · the platform escalates its own sampling and pre-positions therapy circuits before the team is paged.
- Notification cascade · five-hop fail-forward routing with configurable timeouts; clinician portal access to the trajectory at any moment.
- For HCPs only · investigational device, with regulatory pathway disclosed under partnership NDA.
Enrolling-clinician specialty distribution across Cohort 2024-W. Schematic representation; numbers are illustrative composites and do not reflect a specific licensed dataset.
Redistribution math, on the population scale.
One pre-empted resuscitation is the unit. The case for monitoring rests on shifting the population locus of arrhythmia identification from the emergency department to the elective referral pathway, with quantifiable but imperfect sensitivity. The economics follow the redistribution.
- Per-event redistribution · one elective EP procedure costs a fraction of one ICU admission for an unscheduled arrhythmic event in essentially every system modelled.
- Enrolment criteria are the variable · substrate-risk gating defines the patient population that benefits at acceptable cost; the platform supports configurable gating rules per institutional protocol.
- Population-scale alerts · the trajectory index exports as a population dashboard; risk redistribution is auditable across the enrolled cohort, not only per patient.
- Convertibility economics · wearable phase amortises across multiple patients per device; implant phase is patient-specific.
- Institutional MSA · three pricing tiers, integration with existing EP / cardiology service lines, scaling with enrolled population size.
Illustrative composite ranges drawn from publicly available US cost data for similar procedural and emergency contexts. Not a billing schedule, not a payer rate, not derived from a head-to-head trial. Actual realised savings depend on enrolment criteria, regional cost structure, and the sensitivity / specificity profile of the trajectory index in the enrolled population.
What is shipping next.
A snapshot of the platform extensions, registry data drops, and partnership tiers queued for release through 2027. Locked cards indicate content visible to active institutional partners and to qualified academic collaborators under MSA.
CHEMOCARDIA-ENGINE expansion modules
Additional drug-class panels in the biochemistry channel: loop diuretics, ACE-inhibitors and ARBs, calcineurin inhibitors. Brings the heart-failure post-discharge population fully onto the trajectory framework.
Available Q1 2027 · institutional partnersMulti-cohort registry results
24-month outcomes across all enrolled patients in Cohort 2024-W and Cohort 2024-I, including event-redistribution metrics, alert sensitivity / specificity profiles, and convertibility-step audit data.
Expected Q3 2027Institutional pricing & integration tiers
Pricing structure across three tiers (single-centre wearable evaluation, multi-site network deployment, fellowship-grade extended modality including implantable phase), enrolment-population scaling, and EP-service-line integration depth.
Contact partnerships teamWhere the platform has been presented.
Selected appearances of RhythmGuard X1 in late-breaking clinical-trial venues, peer-reviewed methods literature, and partnership announcements through 2025. All venues, dates, and attribution shown here are illustrative composites for this demonstration.
Cohort 2024-W interim outcomes: trajectory-index alerts and event redistribution
Heart Rhythm Society annual meetingThe convertibility step: signature transfer across wearable-to-implant transition (Cohort 2024-I)
Journal of Cardiac ElectrophysiologyTranscutaneous biochemical inference: methodology and population calibration
Series C partnership announcementRhythmGuard X1 platform deployed across 8 academic partner sites for evaluation
Read the trajectory. Then read the strip. Not the other way around.
Whether you are a clinician evaluating a continuous-monitoring substrate that includes a biochemical channel, a programme accountable for the population economics of arrhythmia care, or a partnership team assessing platform integration — one of the next steps below is the one that fits.